Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Nonsurgical treatment for upper eyelid retraction in patients with inactive Graves’ orbitopathy (CROSBI ID 328224)

Prilog u časopisu | ostalo | međunarodna recenzija

Vokurka Topljak, Sandra ; Galiot Delić, Martina ; Mandić, Krešimir ; Perić, Sanja ; Baretić, Maja ; Juri Mandić, Jelena Nonsurgical treatment for upper eyelid retraction in patients with inactive Graves’ orbitopathy // International ophtalmology, (2023), doi: 10.1007/s10792-022-02625-7

Podaci o odgovornosti

Vokurka Topljak, Sandra ; Galiot Delić, Martina ; Mandić, Krešimir ; Perić, Sanja ; Baretić, Maja ; Juri Mandić, Jelena

engleski

Nonsurgical treatment for upper eyelid retraction in patients with inactive Graves’ orbitopathy

Purpose To evaluate the effectiveness of incobotulinumtoxinA (Xeomin®) in treating upper eyelid retraction in patients with Graves orbitopathy (GO) initially scheduled for surgery via two different application sites. Methods This is a comparative, prospective study, conducted at the Department of Ophthalmology, Medical School, University Hospital Centre Zagreb, EUGOGO site (EUropean Group On Graves' Orbitopathy) in Croatia from January 2020 till January of 2021 in accordance with national health headquarter recommendations. All patients were classified as inactive with marked eyelid retraction and randomly divided into groups according to application sites. Group A underwent transconjunctival application (18 eyes) and group B transcutaneous application (20 eyes) of incobotulinumtoxinA. The primary end point of this study was lowering the eyelid, to alleviate anterior eye segment symptoms and achieve acceptable aesthetic appearance until surgery becomes available. Results There were no nonresponders and we found no statistically significant difference in the degree of lowering the eyelid between the two application sites. Following rules for avoiding spread of SARS-CoV- 19, none of the patients included in this study were infected. Moreover, participants reported diminishing of anterior eye segment irritation and improved aesthetics. Conclusion Treatment of inactive GO patients with incobotulinumtoxinA for upper eyelid retraction is efficient and safe and can be used as an adjuvant treatment while patients wait for surgery, by alleviating symptoms and improving the level of aesthetic satisfaction without causing a threat to anterior eye segment and visual function. The study showed that effect of treatment was the same, whether we applied the toxin transconjunctivaly or transcutaneously.

incobotulinumtoxinA ; Xeomin® ; upper eyelid retraction ; Graves’ disease ; Graves’ orbitopathy

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

nije evidentirano

2023.

nije evidentirano

0165-5701

1573-2630

10.1007/s10792-022-02625-7

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost